CD11a Mouse, anti-Mouse, R718, Clone: M17/4, BD OptiBuild™

Description

• The M17/4 antibody reacts with the 180 kDa αL chain of LFA-1 (CD11a/CD18, αLβ2 integrin), a heterodimeric surface glycoprotein expressed on almost all leukocytes
• CD8a+CD8b- intestinal intraepithelial T lymphocytes, which are believed to be thymus independent, do not express CD11a
• LFA-1 mediates a variety of heterotypic and homotypic intercellular adhesions through interaction with ICAM-1 (CD54) and ICAM-2 (CD102), including participation in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells
• mAb M17/4 blocks a variety of LFA-1-mediated cells interactions in vitro, and costimulatory effects have also been described
• In vivo treatment with M17/4 mAb reduces the severity of graft-versus-host reactions, prolongs allograft survival, inhibits the development of autoimmunity, and blocks substance P-induced leukocyte migration
• The M17/4 and 2D7 (Cat
• No
• 553120) antibodies are reported to recognize different epitopes of the CD11a molecule.